3.3 Subsequent Cycle Toxicities
Ten of 12 patients (83.4%) patients continued past cycle 1. Of these, 5
(50%) had subsequent cycle DLTs. Post-cycle 1 DLTs included prolonged
thrombocytopenia (n=2), typhlitis (n=1), and hematuria (n=1). In
response to these post-cycle 1 DLTs, patients either had dose
modifications (n=4) or were removed from protocol therapy (n=1).